Form 4: Fairmount Funds Boosts Viridian Therapeutics Stake

Fairmount Funds Management LLC and related entities reported an acquisition of 454,545 shares of Viridian Therapeutics common stock at $22 per share, increasing their indirect beneficial ownership to 3,914,458 shares.

Summary

• Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, and Fairmount Healthcare Fund II L.P. collectively reported the acquisition of Viridian Therapeutics, Inc. common stock.
• The transaction involved the purchase of 454,545 shares of common stock.
• The shares were acquired at a price of $22 per share.
• The transaction date was October 23, 2025.
• Following this transaction, the reporting persons indirectly beneficially own 3,914,458 shares of Viridian Therapeutics common stock through Fairmount Healthcare Fund II LP.
• Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC disclaim beneficial ownership of securities held by Fund II, except to the extent of their pecuniary interest.
• Tomas Kiselak, a Managing Member of Fairmount Funds Management LLC, serves on the board of directors of Viridian Therapeutics, leading to the reporting persons being deemed directors by deputization.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a significant insider purchase by a 10% owner and director. This indicates strong confidence in the company's future performance and valuation from a well-informed party.

Positives

• Significant insider buying by Fairmount Funds Management LLC and its affiliates, indicating strong confidence in Viridian Therapeutics' future prospects.
• The acquisition of 454,545 shares at $22 per share represents a substantial investment of $10,000,000.
• Increased institutional ownership by a 10% owner and director, which can be viewed positively by the market.

Future Outlook

The filing does not contain any explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
• The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of Issuer and is also a Managing Member of Fairmount Funds Management LLC.

Industry Context

This transaction reflects continued institutional investment in the biotechnology sector, where strategic stakes by significant shareholders and directors are closely watched as indicators of confidence in a company's pipeline and market potential.

Related Party Transactions

• Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, and Fairmount Healthcare Fund II L.P., as 10% owners and deemed directors, acquired 454,545 shares of Viridian Therapeutics common stock.

Stakeholder Impact

• Shareholders: Likely positive, as significant insider buying often signals confidence and can lead to increased investor interest and potentially a higher share price.
• Management: Reinforces confidence in the company's strategy and execution from a key institutional investor and board member.

Key Dates

Recommendation

The significant insider purchase by Fairmount Funds Management LLC, a 10% owner and director by deputization, at a substantial value of $10 million, serves as a strong vote of confidence in Viridian Therapeutics. Such a large-scale acquisition by a well-informed party often precedes positive developments or reflects an undervalued stock, making it a compelling 'buy' signal for seasoned investors.

Keywords

Viridian Therapeutics, VRDN, Fairmount Funds Management, Insider Buying, Equity Purchase, Institutional Investment, Form 4, Beneficial Ownership